Amgen and BIND enter into roughly $180 million nanomedicine deal
CAMBRIDGE, Mass.—BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective, targeted and programmable therapeutics called Accurins, announced Jan. 8 that it has entered into a global collaboration agreement with Amgen Inc. to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors.
According to BIND, the collaboration will develop "a novel Accurin based on BIND's platform for targeted and programmable nanomedicines and Amgen's undisclosed proprietary kinase inhibitor. The collaboration aims to create a kinase inhibitor nanomedicine with optimized therapeutic properties, applying for the first time tissue targeting to molecularly targeted drugs."
Under the terms of the agreement, Amgen will have the exclusive right to pursue development and commercialization of the Accurin kinase inhibitor against solid tumor targets to be selected by Amgen.
Both companies will work together on preclinical development and Amgen will assume responsibility for future development and commercialization. BIND could receive upfront and development milestone payments totaling $46.5 million, as well as potentially an additional $134 million in regulatory and sales milestone payments for the first therapeutic indication—among other possible payments in the future beyond that roughly $180 million and tiered royalties on potential future sales.
"BIND's technology is well aligned with Amgen's focus on the development of highly targeted and selective oncology therapeutics," said Dr. Joseph P. Miletich, senior vice president of research and development at Amgen. "We look forward to collaborating with the BIND scientific team to leverage this technology to address unmet medical needs of cancer patients."
"We are pleased to collaborate with Amgen, an industry leader with a proven track record of success in oncology, on extending our technology into molecularly targeted drugs, such as kinase inhibitors," said Scott Minick, CEO of BIND. "Through this collaboration, Amgen has recognized the unique potential of BIND's Medicinal Nanoengineering platform to create programmable oncology therapeutics that combine molecular and tissue targeting for unsurpassed selectivity and activity."
BIND's Medicinal Nanoengineering platform reportedly enables the design, engineering and manufacturing of Accurins with "unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities," according to the company.
BIND is developing a pipeline of novel Accurins that hold what BIND feels to be "extraordinary potential to become best-in-class drugs and improve patient outcomes" in the areas of oncology, inflammatory diseases and cardiovascular disorders.
BIND's lead product candidate, BIND-014, is currently in Phase I clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.